|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
Plasma Levels of Cellular Fibronectin in Diabetes
From the Department of Internal Medicine (S.D.J.M.K.,J.-D.B.), the Julius Center for Patient-Oriented Research (A.A.), the Department of Neurology (A.A., R.C.J.M.F.), the Department of Nephrology and Hypertension (J.J.B.), and the Department of Hematology (R.F.), University Medical Center, Utrecht, the Netherlands.
Address correspondence and reprint requests to Jan-Dirk Banga, MD, PhD, Department of Internal Medicine, G02.228, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, the Netherlands. E-mail: j.d.banga{at}digd.azu.nl .
OBJECTIVE— Cellular fibronectin is an endothelium-derived protein involved in subendothelial matrix assembly. Elevated plasma levels of cellular fibronectin therefore reflect loss of endothelial cell polarization or injury to blood vessels. Consequently, elevated plasma levels of circulating cellular fibronectin have been described in clinical syndromes with vascular damage, although not in diabetes or atherosclerosis.
RESEARCH DESIGN AND METHODS— We determined fibronectin levels in 52 patients with type 1 diabetes, 50 patients with type 2 diabetes, 54 patients with a history of ischemic stroke, 23 patients with renal artery stenosis, and 64 healthy subjects.
RESULTS— Circulating cellular fibronectin was significantly elevated in patients with diabetes (4.3 ± 2.8 µg/ml) compared with patients with ischemic stroke (2.0 ± 0.9 µg/ml), patients with renovascular hypertension (1.7 ± 1.1 µg/ml), and healthy subjects (1.4 ± 0.6 µg/ml). Patients with diabetes and at least one cardiovascular risk factor had an almost 2.5-fold increase in cellular fibronectin compared with diabetic subjects without such a risk factor. In multivariate regression analysis, higher triglycerides, current or past cigarette smoking, and higher urinary albumin excretion were independently associated with an increase in circulating cellular fibronectin in diabetes.
CONCLUSIONS— These results suggest that circulating cellular fibronectin may be a marker protein for endothelial cell activation, especially in diabetes. Prospective studies are needed to explore this possibility.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. K. Chauhan, J. Kisucka, M. R. Cozzi, M. T. Walsh, F. A. Moretti, M. Battiston, M. Mazzucato, L. De Marco, F. E. Baralle, D. D. Wagner, et al. Prothrombotic Effects of Fibronectin Isoforms Containing the EDA Domain Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 296 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J M Frijns, K M Kasius, A Algra, R Fijnheer, and G J E Rinkel Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage J. Neurol. Neurosurg. Psychiatry, July 1, 2006; 77(7): 863 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-c. Hsu, H.-f. Yen, M.-c. Yin, C.-m. Tsai, and C.-h. Hsieh Five Cysteine-Containing Compounds Delay Diabetic Deterioration in Balb/cA Mice J. Nutr., December 1, 2004; 134(12): 3245 - 3249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Probst, R Fijnheer, P Schellekens, and A Rothova Intraocular and plasma levels of cellular fibronectin in patients with uveitis and diabetes mellitus Br. J. Ophthalmol., May 1, 2004; 88(5): 667 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-c. Hsu, C.-n. Huang, Y.-c. Hung, and M.-c. Yin Five Cysteine-Containing Compounds Have Antioxidative Activity in Balb/cA Mice J. Nutr., January 1, 2004; 134(1): 149 - 152. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |